Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease.
Sophie RestelliniWaqqas AfifPublished in: Journal of clinical medicine (2021)
The goal of therapeutic drug monitoring (TDM) is to optimize anti-TNF (tumor necrosis factor) biologic treatment in patients with inflammatory bowel disease (IBD). Although commercial assays are readily available for both ustekinumab and vedolizumab, the use of TDM with these newer biologic medications is at its infancy. The clinical utility of TDM with non-anti-TNF mechanisms of action is not clear. This review summarizes the latest available data on the pharmacokinetics of newer biologic and oral small molecules and highlights the threshold concentrations that have been associated with improved outcomes in IBD patients.
Keyphrases
- rheumatoid arthritis
- patients with inflammatory bowel disease
- ulcerative colitis
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- electronic health record
- high throughput
- machine learning
- big data
- metabolic syndrome
- adipose tissue
- weight loss
- insulin resistance
- deep learning
- patient reported